Uncategorised - European Medical Journal

The DPE Framework for Metabolomics in Rheumatology

Two children can carry the same diagnosis of juvenile idiopathic arthritis (JIA), attend the same clinic, and begin the same…

Advancing Alzheimer’s Disease Treatment: Interview with Jeffrey L. Cummings

The most influential change has been the evolution of biomarkers, beginning around 2012 with the approval of amyloid PET, so that we…

System-Level Digitalisation Initiatives in the NHS

The English NHS provides a unique setting in which to study large-scale digital transformation. As a nationally coordinated health…

Bridging Climate Science and Cardiometabolic Health

Cardiovascular disease remains a dominant cause of global morbidity and mortality, yet conventional prevention…

Laboratory technician examining bacterial cultures in a petri dish, illustrating research into antimicrobial resistance.

AMR Linked to $3.5 Trillion in Global Losses: IDWeek 2026

Antimicrobial resistance was linked to $3.5 trillion in global economic losses in 2021, new research reveals.

Cardiac Autonomic Dysfunction Linked to Diabetic Neuropathy Severity

Cardiac autonomic dysfunction was associated with greater diabetic neuropathy severity, regardless of diabetic foot ulcer status.

Closeup of researcher hand pointing at a laptop screen displaying 3D molecular model.

In-silico drug modelling could save NHS £1.2bn

A centre for in-silico drug modelling could deliver significant value if fully funded, a new Office of Health Economics (OHE) report finds.

Ultraprocessed Food Linked to Vascular Brain Injury in Midlife

Higher ultraprocessed food intake has been linked to greater adiposity and vascular brain injury in middle-aged adults.

Healthcare professional adjusting an oxygen mask on a patient, illustrating respiratory complications associated with cystic fibrosis lung disease.

Shared Metabolic Pathway Drives Cystic Fibrosis Lung Disease

A shared metabolic pathway may drive airway damage and persistent bacterial infections in people with cystic fibrosis.

Bladder Cancer Combination Shows Durable Response in Trial

ERBB2-positive bladder cancer showed a 73.1% complete response rate with combination therapy in a phase II trial.